Last reviewed · How we verify
Treatment R
Treatment R is a Calcium channel blocker Small molecule drug developed by Boryung Pharmaceutical Co., Ltd. It is currently FDA-approved for Hypertension. Also known as: FA/H.
Treatment R is a calcium channel blocker that works by relaxing blood vessels and reducing blood pressure.
Treatment R is a small molecule intervention. It is being studied in clinical trials for various conditions, including salivary gland cancers and patient-derived organoid, and is also being evaluated for use with a chest-worn ECG monitoring device.
At a glance
| Generic name | Treatment R |
|---|---|
| Also known as | FA/H |
| Sponsor | Boryung Pharmaceutical Co., Ltd |
| Drug class | Calcium channel blocker |
| Target | L-type calcium channels |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Treatment R is a non-dihydropyridine calcium channel blocker that inhibits the influx of calcium ions into vascular smooth muscle cells, leading to vasodilation and a subsequent decrease in blood pressure. This mechanism of action is thought to be responsible for the therapeutic effects of Treatment R in patients with hypertension.
Approved indications
- Hypertension
Common side effects
- Edema
- Dizziness
- Headache
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma (PHASE1)
- A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (PHASE1)
- BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (PHASE2)
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) (PHASE2, PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Treatment R CI brief — competitive landscape report
- Treatment R updates RSS · CI watch RSS
- Boryung Pharmaceutical Co., Ltd portfolio CI
Frequently asked questions about Treatment R
What is Treatment R?
How does Treatment R work?
What is Treatment R used for?
Who makes Treatment R?
Is Treatment R also known as anything else?
What drug class is Treatment R in?
What development phase is Treatment R in?
What are the side effects of Treatment R?
What does Treatment R target?
Related
- Drug class: All Calcium channel blocker drugs
- Target: All drugs targeting L-type calcium channels
- Manufacturer: Boryung Pharmaceutical Co., Ltd — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
- Also known as: FA/H
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing